Now You See It, Now You Do Not: A Case of Infliximab-Induced Vanishing Bile Duct Syndrome.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2019-07-10
Metadata
Show full item recordCitation
Shah P, Larson B, Wishingrad M, Nissen N, Björnsson E, Sundaram V. Now You See It, Now You Do Not: A Case of Infliximab-Induced Vanishing Bile Duct Syndrome. ACG Case Rep J. 2019;6(7):e00134. Published 2019 Jul 10. doi:10.14309/crj.0000000000000134Abstract
Infliximab is a commonly used antitumor necrosis factor alpha agent, especially in patients with inflammatory bowel disease. It has been associated with drug-induced liver injury including immunologic reactions, with rare cases of acute liver failure. We describe a patient with chronic cholestasis and loss of intrahepatic bile ducts after therapy with infliximab for refractory ulcerative colitis consistent with a diagnosis of vanishing bile duct syndrome. About 3 months after the initial infusion, the patient developed subfulminant liver failure and required liver transplantation.Description
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadAdditional Links
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722359/https://journals.lww.com/acgcr/Fulltext/2019/07000/Now_You_See_It,_Now_You_Do_Not__A_Case_of.21.aspx
Rights
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.ae974a485f413a2113503eed53cd6c53
10.14309/crj.0000000000000134
Scopus Count
Collections
Related articles
- Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report.
- Authors: Xie W, Wang Q, Gao Y, Pan CQ
- Issue date: 2018 Sep 29
- Meropenem-induced vanishing bile duct syndrome.
- Authors: Schumaker AL, Okulicz JF
- Issue date: 2010 Sep
- Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.
- Authors: White JC, Appleman S
- Issue date: 2014 Oct
- Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma.
- Authors: Hubscher SG, Lumley MA, Elias E
- Issue date: 1993 Jan
- Vanishing bile duct syndrome in Hodgkin's lymphoma: A case report and literature review.
- Authors: Bakhit M, McCarty TR, Park S, Njei B, Cho M, Karagozian R, Liapakis A
- Issue date: 2017 Jan 14